|
|
| | Dehydroxymethylepoxyquinomicin Basic information |
| Product Name: | Dehydroxymethylepoxyquinomicin | | Synonyms: | 2-hydroxy-N-[(1S,2S,6S)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]benzaMide;Dehydroxymethylepoxyquinomicin (DHMEQ);DHM2EQ;DHMEQ;Benzamide, 2-hydroxy-N-[(1S,2S,6S)-2-hydroxy-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-;(-)-DHMEQ?(dehydroxymethylepoxyquinomicin);()DHMEQ,( ) DHMEQ;2-hydroxy-N-[(1aS,2S,5aS)-2-hydroxy-5-oxo-1a,2,5,5a-tetrahydrocyclohexa[1,2-b]oxiren-3-yl]benzamide | | CAS: | 287194-40-5 | | MF: | C13H11NO5 | | MW: | 261.23 | | EINECS: | | | Product Categories: | | | Mol File: | 287194-40-5.mol |  |
| | Dehydroxymethylepoxyquinomicin Chemical Properties |
| Melting point | 187 °C | | Boiling point | 617.2±55.0 °C(Predicted) | | density | 1.58±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 32 mg/mL (122.50 mM) | | pka | 8.43±0.30(Predicted) | | form | Solid | | color | Off-white to gray |
| | Dehydroxymethylepoxyquinomicin Usage And Synthesis |
| Uses | (-)-DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-)-DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity[1][2][3]. | | in vivo | (-)-DHMEQ (4 mg/kg or 12 mg/kg; intraperitoneal injection; on day 0 and 3 times a week; for one month; SCID mice) treatment shows a significant increase in the survival rate in mice[2]. | Animal Model: | Male C.B17-scid/scid (5 weeks old) mice injected with MT-2 cells[2] | | Dosage: | 4 mg/kg or 12 mg/kg | | Administration: | Intraperitoneal injection; on day 0 and 3 times a week; for one month | | Result: | Showed a significant increase in the survival rate in mice.
|
| | IC 50 | RelA; RelB | | References | [1] Yinzhi Lin, et al. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review. DOI:10.3390/ijms19030729
[2] Mariko Watanabe, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106(7):2462-71. DOI:10.1182/blood-2004-09-3646
[3] Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40(10):1669-1677. DOI:10.1248/bpb.b17-00170 |
| | Dehydroxymethylepoxyquinomicin Preparation Products And Raw materials |
|